15 results on '"Walet S"'
Search Results
2. Physical training and healthy diet improved bowel symptoms, quality of life and fatigue in children with inflammatory bowel disease
- Author
-
Scheffers, L E, Vos, I K, Utens, E M W J, Dieleman, G C, Walet, S, Escher, J C, van den Berg, L E, Pediatrics, Child and Adolescent Psychiatry / Psychology, Internal Medicine, and Cardiology
- Abstract
OBJECTIVES: Physical activity programs have been suggested as adjunctive therapy in adult IBD patients. We assessed the effects of a 12-week lifestyle intervention in children with IBD. METHODS: This study was a randomized semi-crossover controlled trial, investigating a 12-week lifestyle program (3 physical training sessions per week plus personalized healthy dietary advice) in children with IBD. Endpoints were physical fitness (maximal and submaximal exercise capacity, strength, and core stability), patient-reported outcomes (quality of life, fatigue, and fears for exercise), clinical disease activity (fecal calprotectin and disease activity scores), and nutritional status (energy balance and body composition). Change in maximal exercise capacity (peakVO2) was the primary endpoint, all others were secondary endpoints. RESULTS: Fifteen patients (median age 15 [IQR:12-16]) completed the program. At baseline, peak VO2 was reduced (median 73.3% [58.8-100.9] of predicted). After the 12-week program compared to the control period, peakVO2 did not change significantly, exercise capacity measured by 6-minute walking test and core-stability did. While medical treatment remained unchanged, PUCAI disease activity scores decreased significantly versus the control period (15 [3-25] vs 2.5 [0-5], p=0.012), and fecal calprotectin also decreased significantly but not versus the control period. Quality of life (IMPACT-III) improved on 4 out of 6 domains and total score (+13 points) versus the control period. Parents-reported quality of life on the Child health questionnaire and total fatigue score (PedsQol MFS) also improved significantly versus the control period. CONCLUSIONS: A 12-week lifestyle intervention improved bowel symptoms, quality of life, and fatigue in Pediatric IBD patients.Trial registration number: www.trialregister.nl as Trial NL8181.
- Published
- 2023
3. A 12-week lifestyle intervention:effects on fatigue, fear, and nutritional status in children with a Fontan circulation
- Author
-
Scheffers, L. E., Helbing, W. A., Pereira, T., Walet, S., Utens, E. M.W.J., Dulfer, K., van den Berg, L. E., Scheffers, L. E., Helbing, W. A., Pereira, T., Walet, S., Utens, E. M.W.J., Dulfer, K., and van den Berg, L. E.
- Abstract
Introduction: Children and adolescents with a Fontan circulation are less physically active compared to healthy peers. In the current study, effects of a 12-week lifestyle intervention on fatigue, fears regarding exercise, caloric intake, rest energy expenditure (REE), and body composition were measured in children with a Fontan circulation. Methods: This study was a semi-cross-over randomized controlled trial. The lifestyle intervention consisted of a 12-week high-weight resistance training (three supervised training sessions a week) supported by high-protein diet (>2 g/kg) and tailored recommended caloric intake. Fatigue (measured by the validated PedsQol Multidimensional Fatigue Scale), fears regarding exercise (measured on a fear thermometer), REE (measured using indirect calorimetry), caloric intake and body composition using air displacement plethysmography, and four-skinfold method were measured before and after the intervention and control period. Results: Twenty-seven pediatric Fontan patients, median age 12.9 years (IQR: 10.5–16.2), of the included 28 patients successfully completed the program. Before training, both child- and parent-reported levels of fatigue were significantly worse on all domains (general, sleep/rest, and cognitive fatigue) compared to healthy peers. After training, parent-reported fatigue significantly improved on the general and cognitive fatigue domains [effect size +16 points (7–25), p < 0.001, and +10 points (2–17), p = 0.015, compared to the control period]. Before training, fear regarding exercise scored on the fear thermometer was low for both children and parents (median score 1 and 2, respectively, on a scale of 0–8). After training, child-reported fear decreased further compared to the control period [effect size −1.4 points (−2.3 to −0.6), p = 0.001]. At baseline, children had increased REE +12% compared to reference values, which did not change after exercise
- Published
- 2023
4. Physical training and high-protein diet improved muscle strength, parent-reported fatigue, and physical quality of life in children with Pompe disease
- Author
-
Scheffers, L. E., Somers, O. C., Dulfer, K., Dieleman, G. C., Walet, S., van der Giessen, L. J., van der Ploeg, A. T., van den Hout, J. M.P., van den Berg, L. E., Scheffers, L. E., Somers, O. C., Dulfer, K., Dieleman, G. C., Walet, S., van der Giessen, L. J., van der Ploeg, A. T., van den Hout, J. M.P., and van den Berg, L. E.
- Abstract
Exercise has proven to be an effective adjuvant treatment to enzyme replacement therapy (ERT) in mildly affected adult Pompe patients. The aim of this study was to investigate the effects of a 12-week tailored lifestyle intervention, consisting of physical training and a high protein diet (2 grams/kg), in children with Pompe disease. This randomized controlled semi-crossover trial investigated the effects of a lifestyle intervention on the primary outcome: exercise capacity. Secondary outcomes were: muscle strength, core stability, motor function, physical activity levels, quality of life, fatigue, fear of exercise, caloric intake, energy balance, body composition, and safety. Fourteen Pompe patients with a median age of 10.6 [IQR: 7.2–14.5], of whom six classic infantile patients, participated in the lifestyle intervention. At baseline, patients had a lower exercise capacity compared to healthy peers (median 70.3% [IQR: 54.8%–98.6%] of predicted). After the intervention, absolute Peak VO2 improved significantly (1279 mL/min [1012.5–2006] vs. 1352 mL/min [1101.5–2069], p = 0.039), but not compared to the control period. Muscle strength of the hip flexors, hip abductors, elbow extensors, neck extensors, knee extensors, and core stability improved significantly compared to the control period. Children reported a significant increase on the change in health domain of quality of life, parents reported significantly better scores on the quality of life domains: physical functioning, change in health, family cohesion, and fatigue. A 12-week tailored lifestyle intervention for children with Pompe disease seemed safe and led to improvements in muscle strength, core stability, quality of life, and parent-reported fatigue. Pompe patients with a stable disease trajectory seemed to benefit the most from the intervention.
- Published
- 2023
5. Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents
- Author
-
Boon M, Claes I, Havermans T, Fornés-Ferrer V, Calvo-Lerma J, Asseiceira I, Bulfamante A, Garriga M, Masip E, Woodcock S, Walet S, Barreto C, Colombo C, Crespo P, Van der Wiel E, Hulst J, Martinez-Barona, S, Nobili R, Pereira L, Ruperto M, Vicente S, De Boeck K, Ribes-Koninckx C, MyCyFAPP consortium, Erasmus MC other, and Pediatrics
- Subjects
Male ,Parents ,Pediatrics ,Constipation ,Psychometrics ,Cystic Fibrosis ,Pulmonology ,Gastrointestinal Diseases ,Health Status ,Pathology and Laboratory Medicine ,0302 clinical medicine ,Quality of life ,Surveys and Questionnaires ,Medicine and Health Sciences ,Pert ,Medicine ,030212 general & internal medicine ,Prospective Studies ,Prospective cohort study ,Child ,2. Zero hunger ,Multidisciplinary ,Stomach ,MyCyFAPP consortium ,humanities ,3. Good health ,Genetic Diseases ,Child, Preschool ,population characteristics ,Engineering and Technology ,Female ,medicine.symptom ,Anatomy ,Management Engineering ,Research Article ,Diarrhea ,Adult ,medicine.medical_specialty ,Adolescent ,Visual analogue scale ,Science ,Context (language use) ,Gastroenterology and Hepatology ,03 medical and health sciences ,Signs and Symptoms ,Autosomal Recessive Diseases ,Diagnostic Medicine ,parasitic diseases ,Humans ,Management Planning and Control ,Clinical Genetics ,business.industry ,Biology and Life Sciences ,Fibrosis ,Health Care ,Gastrointestinal Tract ,030228 respiratory system ,Age Groups ,People and Places ,Quality of Life ,Ceiling effect ,Observational study ,Population Groupings ,business ,human activities ,Digestive System ,Developmental Biology - Abstract
BACKGROUND: Most patients with cystic fibrosis (CF) suffer from pancreatic insufficiency, leading to fat malabsorption, malnutrition and abdominal discomfort. Until recently, no specific tool was available for assessing gastro-intestinal related quality of life (GI QOL) in patients with CF. As the Horizon2020 project MyCyFAPP aims to improve GI QOL by using a newly designed mobile application, a sensitive and reliable outcome measure was needed. We aimed to study the applicability of the existing child-specific Pediatric Quality of Life Inventory, Gastrointestinal Symptoms Scales and Module (PedsQL GI) in children with CF. METHODS: A multicenter, prospective observational study was performed in 6 European centers to validate the PedsQL GI in children with CF during 3 months. RESULTS: In total, 248 children and their parents were included. Within-patient variability of PedsQL GI was low (24.11), and there was reasonable agreement between children and parents (ICC 0.681). Nine of 14 subscales were informative (no ceiling effect). The PedsQL GI and the median scores for 4 subscales were significantly lower in patients compared to healthy controls. Positive associations were found between PedsQL GI and age (OR = 1.044, p = 0.004) and between PedsQL GI and BMI z-score (OR = 1.127, p = 0.036). PedsQL GI correlated with most CFQ-R subscales (r 0.268 to 0.623) and with a Visual Analogue Scale (r = 0.20). CONCLUSIONS: PedsQL GI is a valid and applicable instrument to assess GI QOL in children with CF. Future research efforts should examine the responsiveness of the CF PedsQL GI to change in the context of clinical interventions and trials. ispartof: PLOS ONE vol:14 issue:12 ispartof: location:United States status: published
- Published
- 2019
6. Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis
- Author
-
Calvo-Lerma, J, Hulst, J, Boon, M, Colombo, C, Masip, E, Ruperto, M, Fornes-Ferrer, V, van der Wiel, E, Claes, I, Garriga, M, Roca, M, Crespo-Escobar, P, Bulfamante, A, Woodcock, S, Martinez-Barona, S, Andres, A, de Boeck, K, Ribes-Koninckx, C, Asensio-Grau, A, Asseiceira, I, Barreto, C, Martinez, AC, Heredia, A, Martins, T, Nobili, R, Pereira, L, Paz-Yepez, C, Valmarana, L, Valmarana, R, Walet, S, and MyCyFAPP Project
- Abstract
Background A method to adjust Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis is not currently available. Objectives To assess the in vivo efficacy of a method to adjust the dose of enzymatic supplement in CF extrapolated from previous in vitro digestion studies (theoretical optimal dose, TOD). Secondly, to assess how individual patient characteristics influence the expected coefficient of fat absorption (CFA) and thus to identify an individual correction factor to improve TOD. Methods A prospective interventional study in 43 paediatric patients with CF from 5 European centres. They followed a 24h fixed diet with the theoretical optimal dose for each meal. Faecal collection was carried out between colorimetric markers in order to include all the faeces corresponding to the fixed diet. Beta regression models were applied to assess the associations of individual patient characteristics with the CFA. Results Median CFA was 90% (84, 94% 1st, 3rd Q.) with no significant differences among centres. Intestinal transit time was positively associated with CFA (p = 0.007), but no statistical associations were found with and age, gender, phenotype or BMI. Regression model showed no improvement of the in vitro predicted theoretical optimal dose when taking individual patient characteristics into account. Conclusion Strict adherence to the theoretical optimal dose of enzymatic supplement for a prescribed meal, led to median CFA levels at the clinical target of 90% with a low variability between patients. The proposed method can be considered as a first approach for an evidence-based method in PERT dosing based on food characteristics. Results have to be confirmed in free dietary settings.
- Published
- 2019
7. ePS5.08 MyCyFAPP project: use of a mobile application for self-management of PERT improves gastrointestinal related quality of life in children with cystic fibrosis
- Author
-
Boon, M., primary, Calvo-Lermo, J., additional, Claes, I., additional, Havermans, T., additional, Fornes, V., additional, Asseiceira, I., additional, Bulfamente, A., additional, Garriga, M., additional, Massip, E., additional, Walet, S., additional, Barreto, C., additional, Colombo, C., additional, Crespo, P., additional, Janssens, H.M., additional, Ruperto, M., additional, Hulst, J., additional, Nobili, R., additional, Pereira, L., additional, Van der Wiel, E., additional, Vicente, S., additional, De Boeck, K., additional, and Ribes-Koninckx, C., additional
- Published
- 2019
- Full Text
- View/download PDF
8. Assessing gastro-intestinal related quality of life in cystic fibrosis: Validation of PedsQL GI in children and their parents
- Author
-
Boon, M. (Mieke), Claes, I. (Ine), Havermans, T. (Trudy), Fornés-Ferrer, V. (Victoria), Calvo-Lerma, J. (Joaquim), Asseiceira, I. (Inês), Bulfamante, A. (Anna), Garriga, M. (María), Masip, E. (Etna), Woodcock, S. (Sandra), Walet, S. (Sylvia), Barreto, C. (C.), Colombo, C. (Carla), Crespo, P. (Paula), Der Wiel, E.V. (Els Van), Hulst, J.M. (Jessie), Martinez-Barona, S. (Sandra), Nobili, R. (Rita), Pereira, L. (Luisa), Ruperto, M. (Mar), Vicente, S. (Saioa), Boeck, K. (Kris) de, Ribes-Koninckx, C. (Carmen), Boon, M. (Mieke), Claes, I. (Ine), Havermans, T. (Trudy), Fornés-Ferrer, V. (Victoria), Calvo-Lerma, J. (Joaquim), Asseiceira, I. (Inês), Bulfamante, A. (Anna), Garriga, M. (María), Masip, E. (Etna), Woodcock, S. (Sandra), Walet, S. (Sylvia), Barreto, C. (C.), Colombo, C. (Carla), Crespo, P. (Paula), Der Wiel, E.V. (Els Van), Hulst, J.M. (Jessie), Martinez-Barona, S. (Sandra), Nobili, R. (Rita), Pereira, L. (Luisa), Ruperto, M. (Mar), Vicente, S. (Saioa), Boeck, K. (Kris) de, and Ribes-Koninckx, C. (Carmen)
- Abstract
Background: Most patients with cystic fibrosis (CF) suffer from pancreatic insufficiency, leading to fat malabsorption, malnutrition and abdominal discomfort. Until recently, no specific tool was available for assessing gastro-intestinal related quality of life (GI QOL) in patients with CF. As the Horizon2020 project MyCyFAPP aims to improve GI QOL by using a newly designed mobile application, a sensitive and reliable outcome measure was needed. We aimed to study the applicability of the existing child-specific Pediatric Quality of Life Inventory, Gastrointestinal Symptoms Scales and Module (PedsQL GI) in children with CF. Methods: A multicenter, prospective observational study was performed in 6 European centers to validate the PedsQL GI in children with CF during 3 months. Results: In total, 248 children and their parents were included. Within-patient variability of PedsQL GI was low (24.11), and there was reasonable agreement between children and parents (ICC 0.681). Nine of 14 subscales were informative (no ceiling effect). The PedsQL GI and the median scores for 4 subscales were significantly lower in patients compared to healthy controls. Positive associations were found between PedsQL GI and age (OR = 1.044, p = 0.004) and between PedsQL GI and BMI z-score (OR = 1.127, p = 0.036). PedsQL GI correlated with most CFQ-R subscales (r 0.268 to 0.623) and with a Visual Analogue Scale (r = 0.20). Conclusions: PedsQL GI is a valid and applicable instrument to assess GI QOL in children with CF. Future research efforts should examine the responsiveness of the CF PedsQL GI to change in the context of clinical interventions and trials.
- Published
- 2019
- Full Text
- View/download PDF
9. Clinical validation of an evidence-based method to adjust Pancreatic Enzyme Replacement Therapy through a prospective interventional study in paediatric patients with Cystic Fibrosis
- Author
-
Calvo-Lerma, J., Hulst, J.M. (Jessie), Boon, M. (Martin), Colombo, C, Masip, E., Ruperto, M., Fornes-Ferrer, V., van der Wiel, E., Claes, I., Garriga, M., Roca, M., Crespo-Escobar, P., Bulfamante, A., Woodcock, S., Martinez-Barona, S., Andres, A., Boeck, K. (Kris) de, Ribes-Koninckx, C., Asensio-Grau, A., Asseiceira, I., Barreto, C. (C.), Martinez, A.C., Heredia, A., Martins, T., Nobili, R., Pereira, L., Paz-Yepez, C., Valmarana, L., Valmarana, R., Walet, S., Calvo-Lerma, J., Hulst, J.M. (Jessie), Boon, M. (Martin), Colombo, C, Masip, E., Ruperto, M., Fornes-Ferrer, V., van der Wiel, E., Claes, I., Garriga, M., Roca, M., Crespo-Escobar, P., Bulfamante, A., Woodcock, S., Martinez-Barona, S., Andres, A., Boeck, K. (Kris) de, Ribes-Koninckx, C., Asensio-Grau, A., Asseiceira, I., Barreto, C. (C.), Martinez, A.C., Heredia, A., Martins, T., Nobili, R., Pereira, L., Paz-Yepez, C., Valmarana, L., Valmarana, R., and Walet, S.
- Abstract
Background A method to adjust Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis is not currently available. Objectives To assess the in vivo efficacy of a method to adjust the dose of enzymatic supplement in CF extrapolated from previous in vitro digestion studies (theoretical optimal dose, TOD). Secondly, to assess how individual patient characteristics influence the expected coefficient of fat absorption (CFA) and thus to identify an individual correction factor to improve TOD. Methods A prospective interventional study in 43 paediatric patients with CF from 5 European centres. They followed a 24h fixed diet with the theoretical optimal dose for each meal. Faecal collection was carried out between colorimetric markers in order to include all the faeces corresponding to the fixed diet. Beta regression models were applied to assess the associations of individual patient characteristics with the CFA. Results Median CFA was 90% (84, 94% 1st, 3rd Q.) with no significant differences among centres. Intestinal transit time was positively associated with CFA (p = 0.007), but no statistical associations were found with and age, gender, phenotype or BMI. Regression model showed no improvement of the in vitro predicted theoretical optimal dose when taking individual patient characteristics into account. Conclusion Strict adherence to the theoretical optimal dose of enzymatic supplement for a prescribed meal, led to median CFA levels at the clinical target of 90% with a low variability between patients. The proposed method can be considered as a first approach for an evidencebased method in PERT dosing based on food characteristics. Results have to be confirmed in free dietary settings.
- Published
- 2019
- Full Text
- View/download PDF
10. Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines
- Author
-
Calvo-Leima, J, Hulst, JM, Asseiceira, I, Claes, I, Garriga, M, Colombo, C, Fornes, V, Woodcock, S, Martins, T, Boon, M, Ruperto, M, Walet, S, Speziali, C, Witters, P, Masip, E, Barreto, C, de Boeck, K, Ribes-Koninckx, C, and MyCyFAPP Project
- Subjects
Nutritional status ,PERT ,Self-management ,Paediatrics ,Guidelines ,Pancreatic insufficiency ,Cystic fibrosis ,Nutritional requirements macronutrients ,Telemedicine - Abstract
Background: The New European guidelines have established the most updated recommendations on nutrition and pancreatic enzyme replacement therapy (PERT) in CF. In the context of MyCyFAPP project - a European study in children with CF aimed at developing specific tools for improvement of self-management - the objective of the current study was to assess nutritional status, daily energy and macronutrient intake, and PERT dosing with reference to these new guidelines. Methods: Cross sectional study in paediatric patients with CF from 6 European centres. SD-scores for weight-for-age (WFA), height-for-age (HFA) and body mass index-for-age (BMI) were obtained. Through a specific 4-day food and enzyme-dose record, energy and macronutrients intake and PERT-use (LU/g lipids) were automatically calculated by the,MyCyFAPP system. Comparisons were made using linear regression models. Results: The lowest quartiles, for BMI and HFA were between 0 and -1SD in all the centres with no significant differences, and 33.5% of the patients had a SD-score
- Published
- 2017
11. WS02.1 Nutritional status, nutrients intake and enzymatic supplements in a European CF cohort: a cross-sectional overview
- Author
-
Lerma, J. Calvo, primary, Hulst, J., additional, Asseiceira, I., additional, Claes, I., additional, Garriga, M., additional, Colombo, C., additional, Ribes-Koninckx, C., additional, Walet, S., additional, Martins, T., additional, Boon, M., additional, Ruperto, M., additional, Speziali, C., additional, Woodcock, S., additional, Witters, P., additional, Masip, E., additional, Barreto, C., additional, and de Boeck, C., additional
- Published
- 2016
- Full Text
- View/download PDF
12. WS12.6 MyCyFAPP project: validation of the PEDsQL GI symptom scale to evaluate gastro-intestinal symptoms in children with cystic fibrosis
- Author
-
Boon, M., Claes, I., Havermans, T., Fornés-Ferrer, V., Asseiceira, I., Bulfamente, A., Garriga, M., Masip, E., Woodcock, S., Walet, S., Barreto, C., Calvo-Lerma, J., Colombo, C., Crespo, P., Van der Wiel, E., Hulst, J., Martinez-Barona, S., Nobili, R., Pereira, L., Ruperto, M., De Boeck, K., Ribes-Koninckx, C., and MyCyFAPP study group
- Published
- 2018
- Full Text
- View/download PDF
13. Study Protocol of the Exercise Study: Unraveling Limitations for Physical Activity in Children With Chronic Diseases in Order to Target Them With Tailored Interventions-A Randomized Cross Over Trial.
- Author
-
Scheffers LE, Helbing WA, Utens EMWJ, Dieleman GC, Dulfer K, Noske J, van den Broek EA, Walet S, Olieman JF, Escher JC, Pijnenburg MW, van der Ploeg AT, and van den Berg LE
- Abstract
Introduction: Physical activity is associated with many physiological and psychological health benefits across the lifespan. Children with a chronic disease often have lower levels of daily physical activity, and a decreased exercise capacity compared to healthy peers. In order to learn more about limitations for physical activity, we investigate children with four different chronic diseases: children with a Fontan circulation, children with Broncho Pulmonary Dysplasia (BPD), Pompe disease and inflammatory bowel disease (IBD). Each of these diseases is likely to interfere with physical activity in a different way. Knowing the specific limitations for physical activity would make it possible to target these, and increase physical activity by a personalized intervention. The aim of this study is to first investigate limitations for physical activity in children with various chronic diseases. Secondly, to measure the effects of a tailored exercise intervention, possibly including a personalized dietary advice and/or psychological counseling, on exercise capacity, endurance, quality of life, fatigue, fear for exercise, safety, muscle strength, physical activity levels, energy balance, and body composition. Methods and Analysis: This randomized crossover trial will aim to include 72 children, aged 6-18 years, with one of the following diagnosis: a Fontan circulation, BPD, Pompe disease and IBD. Eligible patients will participate in the 12-week tailored exercise intervention and are either randomized to start with a control period or start with the intervention. The tailored 12-week exercise interventions, possibly including a personalized dietary advice and/or psychological counseling, will be designed based on the found limitations for physical activity in each disease group during baseline measurements by the Rotterdam Exercise Team. Effects of the tailored training interventions will be measured on the following endpoints: exercise capacity (measured by cardiopulmonary exercise test), endurance, physical activity levels, muscle strength, quality of life, fatigue, fear for exercise, disease activity, cardiac function (in children with a Fontan circulation), energy balance, and body composition. Ethics and Dissemination: Conducted according to the Declaration of Helsinki and Good Clinical Practice. Medical-ethical approval was obtained. Trial Registration Number: NL8181, https://www.trialregister.nl/trial/8181., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Scheffers, Helbing, Utens, Dieleman, Dulfer, Noske, van den Broek, Walet, Olieman, Escher, Pijnenburg, van der Ploeg and van den Berg.)
- Published
- 2022
- Full Text
- View/download PDF
14. Clinical evaluation of an evidence-based method based on food characteristics to adjust pancreatic enzyme supplements dose in cystic fibrosis.
- Author
-
Calvo-Lerma J, Boon M, Colombo C, de Koning B, Asseiceira I, Garriga M, Roca M, Claes I, Bulfamante A, Walet S, Pereira L, Ruperto M, Masip E, Asensio-Grau A, Giana A, Affourtit P, Heredia A, Vicente S, Andrés A, de Boeck K, Hulst J, and Ribes-Koninckx C
- Subjects
- Child, Europe, Evidence-Based Medicine, Female, Humans, Male, Cystic Fibrosis drug therapy, Diet, Enzyme Replacement Therapy methods, Mobile Applications, Pancreas enzymology
- Abstract
Background: Patients with cystic fibrosis (CF) and pancreatic insufficiency need pancreatic enzyme replacement therapy (PERT) for dietary lipids digestion. There is limited evidence for recommending the adequate PERT dose for every meal, and controlling steatorrhea remains a challenge. This study aimed to evaluate a new PERT dosing method supported by a self-management mobile-app., Methods: Children with CF recruited from 6 European centres were instructed to use the app, including an algorithm for optimal PERT dosing based on in vitro digestion studies for every type of food. At baseline, a 24h self-selected diet was registered in the app, and usual PERT doses were taken by the patient. After 1 month, the same diet was followed, but PERT doses were indicated by the app. Change in faecal fat and coefficient of fat absorption (CFA) were determined., Results: 58 patients (median age 8.1 years) participated. Baseline fat absorption was high: median CFA 96.9%, median 2.4g faecal fat). After intervention CFA did not significantly change, but range of PERT doses was reduced: interquartile ranges narrowing from 1447-3070 at baseline to 1783-2495 LU/g fat when using the app. Patients with a low baseline fat absorption (CFA<90%, n=12) experienced significant improvement in CFA after adhering to the recommended PERT dose (from 86.3 to 94.0%, p=0.031)., Conclusion: the use of a novel evidence-based PERT dosing method, based on in vitro fat digestion studies incorporating food characteristics, was effective in increasing CFA in patients with poor baseline fat absorption and could safely be implemented in clinical practice., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2021
- Full Text
- View/download PDF
15. Nutritional status, nutrient intake and use of enzyme supplements in paediatric patients with Cystic Fibrosis; a European multicentre study with reference to current guidelines.
- Author
-
Calvo-Lerma J, Hulst JM, Asseiceira I, Claes I, Garriga M, Colombo C, Fornés V, Woodcock S, Martins T, Boon M, Ruperto M, Walet S, Speziali C, Witters P, Masip E, Barreto C, de Boeck K, and Ribes-Koninckx C
- Subjects
- Body Mass Index, Child, Cross-Sectional Studies, Dietary Supplements, Europe epidemiology, Female, Humans, Male, Needs Assessment, Nutritional Requirements, Pancreatic Function Tests, Recommended Dietary Allowances, Self-Management methods, Self-Management statistics & numerical data, Cystic Fibrosis diagnosis, Cystic Fibrosis enzymology, Cystic Fibrosis therapy, Energy Intake, Enzyme Replacement Therapy methods, Nutritional Status
- Abstract
Background: The New European guidelines have established the most updated recommendations on nutrition and pancreatic enzyme replacement therapy (PERT) in CF. In the context of MyCyFAPP project - a European study in children with CF aimed at developing specific tools for improvement of self-management - the objective of the current study was to assess nutritional status, daily energy and macronutrient intake, and PERT dosing with reference to these new guidelines., Methods: Cross sectional study in paediatric patients with CF from 6 European centres. SD-scores for weight-for-age (WFA), height-for-age (HFA) and body mass index-for-age (BMI) were obtained. Through a specific 4-day food and enzyme-dose record, energy and macronutrients intake and PERT-use (LU/g lipids) were automatically calculated by the MyCyFAPP system. Comparisons were made using linear regression models., Results: The lowest quartiles for BMI and HFA were between 0 and -1SD in all the centres with no significant differences, and 33.5% of the patients had a SD-score <0 for all three parameters. The minimum energy intake recommendation was not reached by 40% of the children and mean nutrients intake values were 14%, 51% and 34% of the total energy for protein, carbohydrates and lipids respectively. When assessed per centre, reported PERT doses were in the recommended range in only 13.8% to 46.6% of the patients; from 5.6% up to 82.7% of children were above the recommended doses and 3.3% to 75% were below., Conclusion: Among the 6 centres, a large variability and inconsistency with new guidelines on nutrition and PERT-use was found. Our findings document the lack of a general criterion to adjust PERT and suggest the potential benefit of educational and self-managerial tools to ensure adherence to therapies, both for clinical staff and families. They will be taken into account when developing these new tools during the next stages of MyCyFAPP Project., (Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.